Neurocrine Biosciences Stock Price - NBIX

0.00 (0.0%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Neurocrine Biosciences Inc NBIX NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
-4.25 -3.54% 115.86 113.65 118.97 118.97 120.11 00:00:03
Bid Price Ask Price Spread Spread % News
108.94 122.15 13.21 10.81% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
13,678 1,191,735 $ 116.42 $ 138,738,023 906,362 72.14 - 128.29
Last Trade Time Type Quantity Stock Price Currency
17:36:02 1 $ 115.86 USD

Neurocrine Biosciences Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 10.76B 92.87M 91.67M $ 788.09M $ 156.91M 0.34 64.90
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Neurocrine Biosciences News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical NBIX Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week121.22126.75113.65122.59848,742-5.36-4.42%
1 Month110.86128.29108.23119.11925,5945.004.51%
3 Months84.24128.2972.14100.97851,90631.6237.54%
6 Months118.87128.2972.14102.58836,807-3.01-2.53%
1 Year84.59128.2972.14100.43766,18231.2736.97%
3 Years46.11128.2941.7686.67836,30269.75151.27%
5 Years41.38128.2931.2568.80896,04474.48179.99%

Neurocrine Biosciences Description

Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.